TY  - JOUR
A1  - Trojan, Jörg
A1  - Mollon, Patrick
A1  - Daniele, Bruno
A1  - Marteau, Florence
A1  - Martín, Lidia
A1  - Li, Yuxin
A1  - Xu, Qing
A1  - Piscaglia, Fabio
A1  - Zaucha, Renata
A1  - Sarker, Debashis
A1  - Lim, Ho Yeong
A1  - Venerito, Marino
T1  - Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ≥ 400 ng/ml  : a matching-adjusted indirect comparison
T2  - Advances in therapy
N2  - Individual patient data (IPD) from the CELESTIAL trial (cabozantinib) and population-level data from the REACH-2 trial (ramucirumab) were used. To align with REACH-2, the CELESTIAL population was limited to patients who received first-line sorafenib only and had baseline serum AFP ≥ 400 ng/mL. The IPD from CELESTIAL were weighted to balance the distribution of 11 effect-modifying baseline characteristics with those of REACH-2. Overall survival (OS; primary endpoint) and progression-free survival (PFS) were compared for the CELESTIAL (matching-adjusted) and REACH-2 populations using weighted Kaplan-Meier (KM) curves and parametric (OS, Weibull; PFS, log-logistic) modeling. Rates of treatment-related adverse events (TRAEs) and TRAE-related discontinuations were also compared.
KW  - Alpha-fetoprotein (AFP)
KW  - Cabozantinib
KW  - Hepatocellular carcinoma (HCC)
KW  - Indirect treatment comparison (ITC)
KW  - Matching-adjusted indirect comparison (MAIC)
KW  - Monoclonal antibody (mAb)
KW  - Ramucirumab
KW  - second-line treatment / 2L treatment
KW  - Tyrosine kinase inhibitor (TKI)
KW  - Vascular endothelial growth factor (VEGF)
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63645
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-636457
SN  - 1865-8652
N1  - Open Access funding enabled and organized by Projekt DEAL. This study and the journal’s Rapid Service Fee was funded by Ipsen. The CELESTIAL study was sponsored by Exelixis. Ipsen was involved in the design of the study and the analysis and interpretation of the data as well as the review of the manuscript.
VL  - 38.2021
IS  - 5
SP  - 2472
EP  - 2490
PB  - Springer Healthcare Communications
CY  - Tarporley
ER  -